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Cellular immune responses are an important correlate of hepatitis C virus (HCV) infection outcome. These
responses are governed by the host’s human leukocyte antigen (HLA) type, and HLA-restricted viral escape
mutants are a critical aspect of this host-virus interaction. We examined the driving forces of HCV evolution
by characterizing the in vivo selective pressure(s) exerted on single amino acid residues within nonstructural
protein 3 (NS3) by the HLA types present in two host populations. Associations between polymorphisms within
NS3 and HLA class I alleles were assessed in 118 individuals from Western Australia and Switzerland with
chronic hepatitis C infection, of whom 82 (69%) were coinfected with human immunodeﬁciency virus. The
levels and locations of amino acid polymorphisms exhibited within NS3 were remarkably similar between the
two cohorts and revealed regions under functional constraint and selective pressures. We identiﬁed speciﬁc
HCV mutations within and ﬂanking published epitopes with the correct HLA restriction and predicted escaped
amino acid. Additional HLA-restricted mutations were identiﬁed that mark putative epitopes targeted by
cell-mediated immune responses. This analysis of host-virus interaction reveals evidence of HCV adaptation to
HLA class I-restricted immune pressure and identiﬁes in vivo targets of cellular immune responses at the
population level.
Clinical and virological outcomes are variable following
acute infection with hepatitis C virus (HCV): there is success-
ful viral clearance in some individuals, while persistent infec-
tion is established in the majority of cases (35). Chronic infec-
tion is characterized by attenuated and narrowly focused
CD4
 and CD8
 T-cell responses (reviewed in reference 14)
in conjunction with reduced proliferative, cytokine, and cyto-
lytic capacity of HCV-speciﬁc T cells (10, 20, 40) and loss of
antigen recognition (3). Conversely, CD4
 and CD8
 T-cell
responses are maintained in individuals who clear the virus (6,
17, 21, 32, 34, 42). Therefore, effective T-cell-dependent im-
mune responses to HCV-speciﬁc viral epitopes, restricted by
the presence of host human leukocyte antigens (HLA) class I
(CD8
 cytotoxic T cells [CTL]) and class II (CD4
 helper T
cells), appear to make an important contribution to adaptive
immunity and disease outcome.
The high rate of HCV replication and mutation renders its
genome susceptible to changes within and ﬂanking HLA-re-
stricted epitopes, thereby providing mutated HCV sequences
with a means of “escaping” HLA-restricted immune responses.
The relevance of HCV immune escape mutations in chronic
infection (reviewed in reference 2) was ﬁrst demonstrated in
chimpanzees (7, 9, 41) and then subsequently demonstrated in
humans (4, 33). Evidence for CTL escape and reversion has
been recently demonstrated in acute infection (36) and 18 to
22 years after a common-source outbreak (24). As in human
immunodeﬁciency virus (HIV) (1), ﬂanking epitope escape
mutations affecting proteasomal epitope processing provide an
effective mechanism of immune escape in HCV (26). However,
direct evidence for viral escape in humans is limited, as the
sequence of the transmitted virus is rarely known and most
previous studies have focused on a limited number of HLA
alleles (38; www.hcv.lanl.gov).
We have chosen a population-based approach to assess in
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11094vivo associations between viral polymorphisms and HLA al-
leles based on our experience in chronic HIV-1 infection (22).
We hypothesized that, within the functional constraints of the
viral proteins, mutations that result in escape from HLA-re-
stricted immune responses will be evident at a population level
as HLA-associated mutations and mark in vivo targets of the
cellular immune responses. In this study, we examined viral
adaptation to HLA-restricted immune responses in individuals
with chronic HCV genotype 1 infection from two host popu-
lations that show a similar HLA distribution to determine the
selective pressure(s) exerted on HCV.
MATERIALS AND METHODS
Subjects. DNA and plasma samples were obtained from individuals with
chronic HCV infection in the Swiss HIV Cohort Study (n  59) and individuals
from the Western Australia (WA) HIV Cohort and other chronic HCV infection
cohorts in WA (n  59). There were no differences between the cohorts in age,
ethnicity, or sex (P  0.1, 
2 and Mann-Whitney tests). All Swiss individuals and
39% of the WA individuals were coinfected with HIV. The CD4
 T-cell counts
in individuals with HCV/HIV coinfection were similar between the cohorts:
median (interquartile range) for Swiss, 429 (305 to 560) cells/l; median for WA,
378 (204 to 483) cells/l( P  0.13).
DNA and viral RNA extraction. DNA was obtained from whole blood using
the QIAamp DNA blood mini kit following the manufacturer’s guidelines. Viral
RNA was extracted from plasma samples using either the QIAamp viral RNA
mini kit (QIAGEN) or the COBAS AMPLICOR HCV specimen preparation kit
v2.0 (Roche) according to the manufacturer’s instructions.
Bulk viral sequencing and HCV genotyping. An initial reverse transcription-
PCR was performed using the primers 2412F2 and 9192R in combination with
the SuperScript III one-step reverse transcription-PCR system with the Platinum
Taq DNA polymerase PCR kit (Invitrogen). The ﬁrst-round product was then
used in nested second-round PCRs containing either the primer pairs HCV-
2412F/HCV-3825R and HCV-3724F/HCV-5310R or alternatively the genotype
1-speciﬁc primers 5517M13F/6531M13R and 6430M13F/7481M13R together
with the Platinum Taq DNA polymerase high-ﬁdelity kit (Invitrogen). PCR
products were puriﬁed using the Exosap method (Amersham), and BigDye
Terminator (v3.1) sequencing reactions were set up with PCR or M13 primers.
The samples were run on an ABI 3730 genetic analyzer, and electropherograms
were analyzed using Seqscape v2.0 (ABI). Primer sequences can be obtained
from the authors upon request. HCV subtypes were assigned by clinical tests
using commercial assays (INNO-LiPA HCV II; Innogenetics, Ghent, Belgium)
and conﬁrmed by phylogenetic analysis.
HLA genotyping. HLA class I typing was performed by direct DNA sequencing
using previously described methods (43). Exons 2 and 3 were sequenced sepa-
rately using speciﬁc sequencing primers and performed as described above.
Allele assignments were obtained using the program Assign (Conexio Geno-
mics). In the large majority of cases, ambiguities were resolved following se-
quencing with allele-speciﬁc subtyping primers. However, in 5% of typings,
identity at exons 2 and 3 was consistent with the presence of rare alternative and
null alleles, and only in these rare cases was the allele assignment consistently
allocated for the most common expressed allele and haplotype combination in
the relevant population.
Associations of HLA alleles with amino acid polymorphisms. Using methods
previously described for the analysis of HIV (22), we created a map of the
HCV amino acid residues in which polymorphism was associated with HLA
alleles for the combined WA and Swiss samples. At each residue, the amino
acid with the highest frequency was assigned as the consensus. The “propor-
tion polymorphism” was determined by calculating the proportion of the
population that had an amino acid different from the consensus. Residues
with mixtures of the consensus and a nonconsensus residue were set as
nonconsensus. Fisher’s exact test was used to assess the signiﬁcance of the
crude associations. In addition, the power to detect an odds ratio (OR) of
2.0 or 0.5 was calculated. Multiple logistic regression models were used to
quantitate adjusted associations between each amino acid residue (response
variable) and the HLA alleles in the population (predictors). Due to col-
linearities introduced by HLA haplotypes, we ran three sets of models in-
cluding HLA alleles from a single HLA class I locus only. Stepwise methods
were used to ﬁnd the most parsimonious set of HLA variables that were
predictive of polymorphism. HLA variables were allowed to enter the model
only if the Fisher’s P value was 0.1, the minimum observed or expected cell
count was 5, and the power for an OR of 2.0 or 0.5 was 20%. Models
were constructed by entering variables in order from the lowest Fisher’s P
value up to the point where the number of observations just exceeded 10 per
variable. Then, using a standard backward elimination, variables were re-
moved in order from the highest adjusted P value until all variables remaining
in the model had a P value of 0.1. All of the above criteria for model
FIG. 1. Similar HLA-A, -B, and -C allele distributions within the
Swiss and WA cohorts. Bars indicate the percentage of individuals with
the respective HLA alleles, with dark gray bars indicating the HLA
allele distributions within the Swiss cohort and light gray bars indicat-
ing the WA cohort. The bar corresponding to “others” groups the
alleles occurring at low frequencies. The extremely polymorphic nature
of HLA-B is reﬂected in a larger number of alleles at low frequency
compared to HLA-A or -C. The HLA allele distributions for the three
loci did not differ signiﬁcantly between the two cohorts (P  0.5, 0.1,
and 0.6 for HLA-A, -B, and -C alleles, respectively, by Fisher’s exact
test).
VOL. 80, 2006 HLA-DRIVEN ADAPTATION OF HEPATITIS C VIRUS 11095building are the same as those previously published (22), except that, due to
the relatively smaller size of the data set, the power cutoff used here was 20%
rather than 30%. In addition, due to the inclusion of both genotype 1a and 1b
HCV sequences, we reanalyzed those sites in which the consensus amino acid
differed between the subtypes by reassigning the corresponding consensus
amino acid for each HCV subtype.
Use of the traditional Bonferroni correction for multiple comparisons will
likely be overly conservative in this application due to the large number of
intercorrelated test statistics. Instead, in order to assess the proportions of
associations likely to be incorrectly classiﬁed as signiﬁcant due to multiple com-
parisons, we estimated the allele-wise false discovery rate among the associations
tested (for details, see reference 8).
RESULTS AND DISCUSSION
We examined the NS3 protein of HCV because it contains
several known immunogenic epitopes for the HLA-B and -A
alleles and, therefore, provided an opportunity to compare our
results against existing data obtained from in vitro cellular
approaches. We included 59 individuals from Switzerland
(Swiss) and 59 from Western Australia (WA) with chronic
HCV infection and prior to the commencement of antiviral
therapy for HCV infection. Of the 118 individuals in this study,
88 (75%) were infected with HCV genotype 1a and 30 (25%)
were infected with genotype 1b. The proﬁles of the HLA-A, -B,
and -C allele distributions in the two cohorts were not statis-
tically different, with a concordance of most frequent alleles for
each locus (Fig. 1). Both cohorts comprise predominantly Cau-
casian (Swiss, 98%; WA, 92%) and male (Swiss, 76%; WA,
73%) individuals. All Swiss individuals were recruited from the
Swiss HIV Cohort Study, and 39% of the WA individuals were
coinfected with HIV.
Similar viral diversity in two host populations reﬂects func-
tional constraints and selective pressures within HCV. The
polymorphism proﬁles for the two populations were remark-
ably similar, as shown in Fig. 2A, with conserved regions within
NS3 consistent with known functionally constrained areas of
FIG. 2. Levels of amino acid polymorphism exhibited within NS3 are remarkably similar between the Swiss and WA cohorts. (A) Amino acid
polymorphism proﬁles of the two cohorts within the NS3 region. Known conserved motifs of the NS3 helicase region are indicated by gray boxes
and named according to the respective publications (13, 39). The inset provides a detailed analysis of the polymorphism proﬁle of amino acids 1057
to 1127, with arrows indicating active sites within NS3 protease (16). (B) Sites within NS3 where the polymorphism rates between the two cohorts
differ by more than 10%. Higher polymorphism within the WA cohort is indicated by bars above the line, and when the amount of polymorphism
is greater in the Swiss cohort, bars are below the line. Diamonds mark differences in consensus amino acid between the cohorts.
11096 GAUDIERI ET AL. J. VIROL.the protein such as the motifs crucial for RNA binding and
ATP hydrolysis within NS3 helicase (13, 39). Within NS3 pro-
tease, active sites (16) were completely conserved and in many
cases ﬂanked by polymorphic residues (Fig. 2A). Other regions
in which little variation was observed might either reﬂect as yet
unknown structurally or functionally relevant sites or lack of
immune pressure. Few sites within the NS3 protein varied in
the amount of polymorphism or consensus amino acid exhib-
ited by the two cohorts (Fig. 2B).
Phylogenetic analysis of the HCV NS3 sequences from both
cohorts revealed clustering within the main genotype 1a cluster
when examining changes at sites that are generally regarded as
neutral or “near neutral”(synonymous; changes that do not
alter amino acid). These clusters contained predominantly se-
quences from one cohort or the other and could reﬂect local
transmission groups and founder effects (Fig. 3A). Interest-
ingly, when we analyzed only those sites reﬂecting amino acid
change (nonsynonymous), there appeared to be greater admix-
ture, possibly reﬂecting common selective pressures irrespec-
tive of transmission and founder effects (Fig. 3B). We acknowl-
FIG. 3. Phylogenetic analyses of the NS3 region in HCV reveals clustering of neutral or “near-neutral” changes that appear to disperse
when examining sites are under selective pressure. Nucleotide sequences greater than 1,000 bp in the NS3 region were aligned using the
program ClustalW, and the resultant alignment was then used in the phylogenetic package Mega 3.1 (15). Phylogenetic analysis of the NS3
region was performed using the neighbor-joining method based on the modiﬁed Nei-Gojobori model for synonymous and nonsynonymous
sites with pairwise deletion. Bootstrap replications (n  1,000) were performed for both analyses. Sequences with less than 1,000 bp were
not included; thus, not all individuals contributed to this analysis. (A) Analysis of synonymous changes reveals distinct clusters. Within the
genotype 1a cluster, sequences form additional clusters which largely disappear when analyzing only nonsynonymous changes (B). Viral
sequences that fall into clusters in panel A are marked with identical colors; sequences that do not fall into clusters are not colored. Triangles
mark sequences from Swiss individuals, and circles mark sequences from WA individuals. For both trees, numbers at nodes are bootstrap
values, indicating the percentage of 1,000 replications. Only bootstrap values above 60% are shown. The bars at the bottom of the ﬁgure
indicate the number of substitutions per site.
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the smaller number of changes included in the nonsynonymous
analysis than for the synonymous tree (reﬂected in the genetic
distances in Fig. 3). However, the lack of clustering illustrated
in the nonsynonymous tree reﬂects the similar HCV polymor-
phism proﬁles and consensus sequences in both cohorts, as
shown in Fig. 2B.
Evidence for HLA-driven viral adaptation in HCV infection.
We created a map of the HCV amino acid residues in which
polymorphism was associated with HLA alleles for the com-
bined WA and Swiss samples. Associations were considered
signiﬁcant if the P values were 0.05 in multivariate analyses
and after adjusting for subtype-speciﬁc differences. Positive
associations were deﬁned as HLA-associated mutations that
vary from the consensus sequence, consistent with the notion
of CTL escape. HLA-speciﬁc polymorphisms in which the con-
sensus was overrepresented in the HLA-positive group were
termed “negative” associations (22). We and others (18, 22)
have previously hypothesized that the consensus viral sequence
is “best adapted” to T-cell responses encountered in the con-
FIG. 4. Signiﬁcant (P  0.05) associations of HLA alleles with viral polymorphisms within NS3 mark relevant immunological sites within the
virus. (A) HLA associations with viral polymorphisms (P  0.05) are shown as asterisks; those within or ﬂanking (5 amino acids) published epitopes
are boxed. The HLA allele and position of the association are shown. Five of the seven positions shown had an association with an allele-wise false
discovery rate of less than 10%, while two positions (NS3-1094 and NS3-1635) had false discovery rates above this cutoff. (B) The top panel shows
published HLA-restricted epitopes as listed in the HCV database at http://www.hcv.lanl.gov. Speciﬁc HLA associations with viral mutations found
within the NS3 region are shown as either positive associations (variation from consensus amino acid is overrepresented in the HLA-positive
group) or negative associations (maintenance of consensus amino acid is overrepresented in the HLA-positive group) for HLA-A, -B, and -C
alleles. Red indicates associations that fall within published epitopes, and blue indicates an association ﬂanking a published epitope. Vertical bars
indicate the amount of amino acid variation within the combined cohort for each site, and the indicated amino acid is consensus. Red vertical bars
indicate nonconservative amino acid changes, and blue bars indicate conservative amino acid changes (22). Odds ratios are indicated below the
HLA allele. Hashed boxes indicate likely HLA haplotype structures. The conserved helicase motifs within this region are indicated and span highly
conserved residues in the combined cohort.
11098 GAUDIERI ET AL. J. VIROL.text of the most common or evolutionarily conserved HLA
alleles in the host population.
Analysis of the 631 amino acids within NS3 revealed 17
statistically signiﬁcant associations with HLA-A, -B, and -C
alleles that satisﬁed the conditions imposed by the statistical
method. Of these, ﬁve fell within, or ﬂanked, published
HLA class I-restricted epitopes (Fig. 4). Fourteen associa-
tions fell within a region of 100 amino acids, of which 11
were within 60 amino acids in NS3 that are predominantly
positioned in an external alpha-helix domain of helicase
(Fig. 4 and 5). While, as outlined below, some of this clus-
tering reﬂects the strong interlocus linkage disequilibrium
(LD) that exists within well-deﬁned HLA haplotypes, clus-
tering could also be attributable to differences in the immuno-
genicity or functional and structural constraints of particular
regions within the viral proteins.
Figures 4 and 6 illustrate the effectiveness of this ap-
proach in predicting epitope positions, correctly assigning
HLA class I restriction and identifying “preferred” in vivo
escaped viral mutations. For example, analysis of the amino
acid sequence in HLA-B*0801-positive and -negative indi-
viduals revealed two relevant sites at P3 (K1397R) and P4
(K1398R) within the published HLA-B8 epitope at NS3-
1395 (HSKKKCDEL), which have both been previously de-
scribed as escape mutations (24, 36), although in our study
only the K1397R association was signiﬁcant (P  0.007)
(Fig. 6A). Of interest, these amino acid substitutions appear
to be mutually exclusive, suggesting mutation at one of the
lysine residues may be sufﬁcient to abrogate CTL recogni-
tion and/or there is a high ﬁtness cost for altering both
residues. Furthermore, 65% of individuals carrying the
HLA-B*0801 allele exhibited sequence variation within this
epitope, compared with 7% of the HLA-B*0801-negative
individuals (P  0.001, Fisher’s exact test). This suggests
that sequence polymorphism within this epitope is driven by
escape from HLA-B*0801-restricted immune pressure and
is concordant with the previously observed reversion event
within this epitope following transmission to an individual
that lacked the HLA-B8 allele (36). These observations and
the position of this epitope within a likely structurally con-
strained region of the protein (Fig. 5) suggest a viral ﬁtness
hurdle that would favor consensus residues in individuals
lacking the appropriate HLA allele.
Another signiﬁcant HLA-B*0801 association was found in
the critical P9 anchor position of the HLA-B*0801 NS3-1402
epitope (ELAAKLVAL). We also observed a negative HLA-
A*0101 association with the correct escaped amino acid at P9
(F1444Y) of an immunogenic HLA-A1 epitope at NS3-1436
(ATDALMTGY) (17) (Fig. 6B). Furthermore, we found two
HLA associations with residues ﬂanking known epitopes: an
HLA-A*1101 association at position P1 of the previously
described HLA-A11-restricted epitope at NS3-1636 and an
HLA-B*0701 association ﬂanking the known HLA-B7-re-
stricted epitope at NS3-1373 (www.hcv.lanl.gov; Fig. 4). Im-
portantly, the phylogenetic analysis of the NS3 sequences does
not reveal clustering of individuals that share the same HLA-
restricted polymorphism (Fig. 6). This suggests that founder
effects were not the major contributing factor for viral poly-
morphism within these epitopes.
Twelve putative CTL escape mutations were also identiﬁed
in this analysis (Fig. 4), providing a basis for experimental
approaches that may reveal novel HLA-restricted epitopes and
associated CTL escape variants. Over 60% of the previously
reported HLA class I epitopes within NS3 were HLA-A re-
stricted (38; www.hcv.lanl.gov), while in our study, more than
75% of signiﬁcant HLA-restricted associations were with
HLA-B and -C alleles (Fig. 4). Although our study does not
allow us to assess the relative importance of HLA-B- and
-C-restricted cellular immune responses, recent reports show-
ing the dominance of HLA-B-restricted immune responses in
HCV (23) and HIV infection (11) suggest that future studies
should examine the relative inﬂuence of HLA-A-, -B-, and
-C-restricted responses.
When comparing the results of our study with previous
cellular based studies, we found concordant results for
HLA-B8 epitopes (signiﬁcantly more associations within
than outside epitopes); however, we found no signiﬁcant
associations within published HLA-A2 epitopes (Fig. 7).
The premise of this approach is that it identiﬁes in vivo
targets of the immune response, and, therefore, the lack of
signiﬁcant associations for some HLA-A alleles would sug-
gest that HLA-A-restricted mutations within these epitopes
FIG. 5. Location of known epitopes and HLA associations within
NS3. The model of NS3 was taken from the NCBI PubMed Molecular
Graphics Program Cn3D. The positions of the epitopes shown in Fig.
4, 6, and 8 are marked (yellow). Black arrows mark position P1 of the
respective epitopes; red arrows mark signiﬁcant HLA associations.
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infection. Interestingly, our analysis did not detect signiﬁ-
cant HLA-restricted mutations within two HLA-A2 immu-
nodominant epitopes at NS3-1073 and NS3-1406 (Fig. 8).
This is in concordance with recent reports which describe a
limited degree of sequence variability within the A2 NS3-
1073 epitope (30, 31), possibly due to a high viral ﬁtness cost
of mutations within this epitope (30). Hence, high viral
ﬁtness cost may also limit the variability of HCV within
some immunologically relevant epitopes. Using a popula-
tion-based approach, the lack of HLA-restricted associa-
tions in immunodominant epitopes could be used to direct
the search for motifs within the viral sequence in which
mutations may impart a high viral ﬁtness cost or are not
FIG. 6. HLA-restricted mutations in individuals with chronic HCV infection within published HLA class I-restricted epitopes. The ﬁrst line
indicates the published epitopes, and the second line indicates the consensus amino acid from both cohorts, with signiﬁcant associations found in
this study shown by white letters on a black background and with an arrow. Identity with consensus is indicated by dots, and deletions are indicated
by white dashes on a black background; the sequences are sorted by the presence of the respective HLA alleles. Mutations within epitopes are
shown as white letters on a black background, outside epitopes are shown in dark gray, and positions that appear to contain HCV genotype
1b-speciﬁc polymorphisms are boxed. A lowercase letter indicates the presence of two major viral quasispecies including consensus. Sequences
from individuals infected with HCV genotype 1b are marked by a closed circle. Individuals with incomplete sequence for the respective epitopes
were excluded. HLA-B*0801- and HLA-A*0101-positive individuals are marked with circles in the respective phylogenetic trees. Trees include all
sites and were generated as described in the legend to Fig. 3. Individual sequences with mutations at positions with signiﬁcant associations are
marked with closed circles; those with consensus amino acids are marked with open circles. (A) Demonstration of a positive HLA association with
viral polymorphism in two overlapping epitopes (B8-1395 and B8-1402). The K1397R and L1410X substitutions were signiﬁcantly (P  0.007 and
P  0.006 in multivariate analyses, respectively, see Materials and Methods) more frequent in HLA-B*0801-positive than in HLA-B*0801-negative
individuals. One individual has a large deletion spanning two neighboring HLA-B*0801 epitopes (marked with a closed triangle) and could not
be included in the phylogenetic analyses. (B) Demonstration of a negative HLA association with viral polymorphism (F1444Y) within the known
HLA-A1-1436 epitope. The consensus amino acid F appears to be maintained within the HLA-A*0101-positive individuals compared to the
increased incidence of mutation from consensus (Y) in the HLA-A*0101-negative individuals. The phylogenetic analyses do not reveal clustering
of individual sequences that share the same HLA-restricted polymorphism.
11100 GAUDIERI ET AL. J. VIROL.subject to ongoing immune pressure in vivo. This approach
is unlikely to identify new epitopes within highly conserved
regions, as the premise for the identiﬁcation of HLA-re-
stricted mutations marking putative epitopes is based on
viral polymorphism. Comprehensive analysis of the relevant
epitopes needs to be complemented by cellular assays using
overlapping peptides which span these highly conserved re-
gions.
Another critical biological observation was the association of
particular HLA-B and -C alleles (and to a lesser extent
HLA-A) at identical positions within NS3. These are likely to
reﬂect the strong interlocus LD that exists within well-deﬁned
HLA haplotypes (5). These include the common Caucasian
haplotypes HLA-A*0101, -B*0801, and -C*0701 and HLA-
A*0301, -B*0701, and -C*0702. Figure 4 clearly shows the
haplotype structure at positions 1384, 1397, and 1410 within
NS3. As the LD between HLA-B and -A is less than that
observed for HLA-B and -C, one would expect these observa-
tions to occur predominantly for HLA-B and -C as shown in
Fig. 4. Hence studies describing epitopes restricted to a par-
ticular HLA-B or -C allele using cellular assays on a small
number of individuals may be subject to the confounding issue
of haplotype structure. These characteristics within the major
histocompatibility complex have made it difﬁcult to assign a
primary causative gene to the large number of diseases asso-
ciated with the region (5).
We may expect that CTL immune pressure in coinfected
individuals is compromised compared to that in HCV-
monoinfected individuals and in this case would likely re-
ﬂect a reduced number of HLA-restricted associations.
However, previous studies showed an overall similar
breadth and magnitude of CTL responses in HIV-negative
and HIV-positive patients (12), although declining CD4

T-cell counts were associated with lower levels of HCV-
FIG. 7. Statistical signiﬁcance of HLA associations with viral polymorphism within published epitopes for HLA-B8 (A) and HLA-A2 (B). We
assessed the likelihood of ﬁnding true associations between HCV polymorphism and HLA alleles HLA-A2 and -B8 by comparing the distributions
of the Fisher’s exact P values for amino acid residues lying within and outside of published HLA-A2 and -B8 epitopes. For example, the 631
univariate P values for the HLA-B8 associations with polymorphism in NS3 were classiﬁed as to whether the position was within or outside of the
published HLA-B8 epitopes (www.hcv.lanl.gov). Using the P values as the “time” base, Kaplan-Meier product limit estimators compare the
distributions of the P values for the groups; observations were censored for P values of 0.50. The curves compare the P values for associations
of the HLA alleles lying outside of (solid line) and within (broken line) the published epitopes for the allele noted. The differences in the curves
were evaluated using proportional hazards models that included covariates for position within a published epitope (dichotomous indicator) and
the estimated power to detect an OR of 2.0 or 0.5. For HLA-B8, the early and overall separation of the curves indicates that the P values for
residues within the epitopes are smaller overall than those outside epitopes, and this difference is signiﬁcant after adjustment for the power of the
tests for association (proportional hazards model adjusted P value  0.009). In contrast, no statistically signiﬁcant difference was observed for the
P values for HLA-A2 associations when stratiﬁed by residue location within or outside of A2 epitopes (P  0.602). Finally, there were no
differences between the P values comparing (i) HLA-B8 associations within and outside of HLA-A2 epitopes and (ii) HLA-A2 associations within
and outside of HLA-B8 epitopes (data not shown).
VOL. 80, 2006 HLA-DRIVEN ADAPTATION OF HEPATITIS C VIRUS 11101FIG. 8. Lack of signiﬁcant HLA associations within known immunodominant HLA-A2 epitopes. (A) A2-1073. (B) A2-1406. Examination of the
two HLA-A2 epitopes ﬁnds no signiﬁcant accumulation by multivariate analysis (see Materials and Methods) of mutations at single residues within
the HLA-A*0201-carrying individuals. All three patients with the Y1082F mutation affecting proteasomal processing were infected with HCV
genotype 1b, as were the individuals in the experimental setting described by Seifert and colleagues (26). The ﬁrst line indicates the published
epitopes, and the second line indicates the consensus amino acid from both cohorts. Identity with consensus is indicated by dots, and deletions are
indicated by white dashes on a black background; the sequences are sorted by the presence of the respective HLA alleles. Mutations within epitopes
are shown by white letters on a black background, outside epitopes are shown in dark gray, and mutations that appear speciﬁc to HCV genotype
1b are boxed. A lowercase letter indicates the presence of two major viral quasispecies, including the consensus. Sequences from individuals
infected with HCV genotype 1b are marked by a closed circle; one individual with a large deletion is marked by a closed triangle. Individuals with
incomplete sequence for the respective epitopes were excluded.
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 T cells. Similarly, diminished immunological
pressure in advanced HIV disease (CD4
 T-cell count be-
low 200 cells/l) has been associated with a decrease in
HCV quasispecies (25, 37). The large majority (90%) of the
coinfected individuals in this study had a CD4
 T-cell count
above 200 cells/l, and most (67%) individuals were treated
with antiretroviral therapy and had undetectable HIV RNA.
Given these characteristics, we would expect that the HLA
class I-driven immune pressure in the coinfected individuals
would be similar to that for the monoinfected individuals.
However, although the majority of the patients coinfected
with HIV were under successful antiretroviral therapy, we
cannot exclude the possibility that coinfection alters the
shape of the T-cell repertoire and the hierarchy of recog-
nized T-cell epitopes, as has recently been described by
Selin and Welsh (27).
In conclusion, we have utilized a population-based approach
to identify (i) polymorphic and conserved sites that are likely to
reﬂect structural or functional constraints in the HCV genome,
(ii) signiﬁcant associations of speciﬁc HLA alleles with HCV
mutations within and ﬂanking published T-cell epitopes (in-
cluding likely critical anchor residues), and (iii) putative HLA-
restricted CTL escape mutations within NS3. Furthermore, the
HLA associations are relevant to two geographically distinct
chronic HCV infection cohorts with similar HLA distributions.
Given the paucity of published HLA-restricted epitopes within
HCV, this method will provide a resource that could both
complement and validate cellular approaches aimed at char-
acterizing the host’s immune response in chronic infection.
However, given the large amount of diversity between the
HCV genotypes (28, 29), we would envisage that this analysis
will need to be performed on large cohorts of speciﬁc viral
genotypes.
In HIV, this approach has been substantiated by the con-
ﬁrmation of predicted viral escape mutations, including the
ﬁrst description of viral escape mediated by disruption to
intracellular epitope processing caused by a mutation out-
side an epitope (1). In several instances to date, the use of
this approach was able to predict the location, amino acid
substitution, HLA subtype association, and biological mech-
anism of escape and reversion kinetics (19). The analysis
here should identify in vivo targets of cellular immune re-
sponses in chronic HCV infection and provide critical infor-
mation for the design of future vaccines.
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